OPG and RANK polymorphisms are both associated with cortical bone mineral density: Findings from a metaanalysis of the avon longitudinal study of parents and children and Gothenburg osteoporosis and obesity determinants cohorts

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 8, 2010, Pages 3940-3948

  Paternoster, Lavinia ^a   Ohlsson, C ^b   Sayers, A ^b   Vandenput, L ^b   Lorentzon, M ^b   Evans, D M ^b   Tobias, J H ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN MARK3; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; UNCLASSIFIED DRUG;

ADOLESCENT; ADOLESCENT DEVELOPMENT; ADULT; ARTICLE; BONE DENSITY; BONE DEVELOPMENT; BONE GROWTH; BONE REMODELING; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICAL BONE MINERAL DENSITY; DISEASE ASSOCIATION; FEMALE; GENETIC MARKER; GENOTYPE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBESITY; OSTEOPOROSIS; PARENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TIBIA;

EID: 77955343223     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-0025     Document Type: Article

References (18)

1. Arden NK, Baker J, Hogg C, Baan K, Spector TD 1996 The heritability of bone mineral density, ultrasound of the calcaneus and hip axis length: a study of postmenopausal twins. J Bone Miner Res 11:530-534
2. Richards JB, Rivadeneira F, Inouye M, Pastinen TM, Soranzo N, Wilson SG, Andrew T, Falchi M, Gwilliam R, Ahmadi KR, Valdes AM, Arp P, Whittaker P, Verlaan DJ, Jhamai M, Kumanduri V, Moorhouse M, van Meurs JB, Hofman A, Pols HA, Hart D, Zhai G, Kato BS, Mullin BH, Zhang F, Deloukas P, Uitterlinden AG, Spector TD 2008 Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet 371:1505-1512
3. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP 2002 High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346:1513-1521
4. Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, Benchekroun Y, Hu X, Adair R, Chee L, FitzGerald MG, Tulig C, Caruso A, Tzellas N, Bawa A, Franklin B, McGuire S, Nogues X, Gong G, Allen KM, Anisowicz A, Morales AJ, Lomedico PT, Recker SM, Van Eerdewegh P, Recker RR, Johnson ML 2002 A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70:11-19
5. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, Ingvarsson T, Jonsdottir T, Saemundsdottir J, Center JR, Nguyen TV, Bagger Y, Gulcher JR, Eisman JA, Christiansen C, Sigurdsson G, Kong A, Thorsteinsdottir U, Stefansson K 2008 Multiple genetic loci for bone mineral density and fractures. N Engl J Med 358:2355-2365
6. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, Ingvarsson T, Jonsdottir T, Saemundsdottir J, Snorradóttir S, Center JR, Nguyen TV, Alexandersen P, Gulcher JR, Eisman JA, Christiansen C, Sigurdsson G, Kong A, Thorsteinsdottir U, Stefansson K 2009 New sequence variants associated with bone mineral density. Nat Genet 41:15-17
7. Boyle WJ, Simonet WS, Lacey DL 2003 Osteoclast differentiation and activation. Nature 423:337-342
8. Rivadeneira F, Styrkársdottir U, Estrada K, Halldórsson BV, Hsu YH, Richards JB, Zillikens MC, Kavvoura FK, Amin N, Aulchenko YS, Cupples LA, Deloukas P, Demissie S, Grundberg E, Hofman A, Kong A, Karasik D, van Meurs JB, Oostra B, Pastinen T, Pols HA, Sigurdsson G, Soranzo N, Thorleifsson G, Thorsteinsdottir U, Williams FM, Wilson SG, Zhou Y, Ralston SH, van Duijn CM, Spector T, Kiel DP, Stefansson K, Ioannidis JP, Uitterlinden AG; Genetic Factors of Osteoporosis (GEFOS) Consortium 2009 Twenty bone-mineral-density loci identified by large-scale metaanalysis of genome-wide association studies. Nat Genet 41: 1199-1208
9. Timpson NJ, Tobias JH, Richards JB, Soranzo N, Duncan EL, Sims AM, Whittaker P, Kumanduri V, Zhai G, Glaser B, Eisman J, Jones G, Nicholson G, Prince R, Seeman E, Spector TD, Brown MA, Peltonen L, Smith GD, Deloukas P, Evans DM 2009 Common variants in the region around Osterix are associated with bone mineral density and growth in childhood. Hum Mol Genet 18:1510-1517
10. Koay MA, Tobias JH, Leary SD, Steer CD, Vilariño-Güell C, Brown MA 2007 The effect of LRP5 polymorphisms on bone mineral density is apparent in childhood. Calcif Tissue Int 81:1-9
11. Bachrach LK 2001 Acquisition of optimal bone mass in childhood and adolescence. Trends Endcrinol Metab 12:22-28
12. Seeman E, Delmas PD 2006 Bone quality: the material and structural basis of bone strength and fragility. N Engl J Med 354:2250-2261
13. Golding J, Pembrey M, Jones R 2001 ALSPAC: the Avon Longitudinal Study of Parents and Children. I. Study methodology. Paediatr Perinat Epidemiol 15: 74-87
14. Jones RW, Ring S, Tyfield L, Hamvas R, Simmons H, Pembrey M, Golding J 2000 A new human genetic resource: a DNA bank established as part of the Avon longitudinal study of pregnancy and childhood (ALSPAC). Eur J Hum Genet 8:653-660
15. Lorentzon M, Mellström D, Ohlsson C 2005 Association of amount of physical activity with cortical bone size and trabecular volumetric BMD in young adult men: the GOOD study. J Bone Miner Res 20:1936-1943
16. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC 2007 PLINK: a toolset for whole-genome association and population-based linkage analysis. Am J Hum Genet 81:559-575
17. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial 2009 Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756-765
18. Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK 2009 Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 24:182-195